The Novartis Malaria Initiative Der Weg zur Eliminierung von Malaria Silvio Gabriel, BASAID April...
-
Upload
ashley-skinner -
Category
Documents
-
view
216 -
download
0
Transcript of The Novartis Malaria Initiative Der Weg zur Eliminierung von Malaria Silvio Gabriel, BASAID April...
The Novartis Malaria Initiative Der Weg zur Eliminierung von Malaria
Silvio Gabriel, BASAID
April 2012
Malaria is an African tragedy!More than 90% of malaria deaths occur in Africa2/60a
Malaria is preventable and treatable, yet nearly 655,000 lives are lost to the disease every year2/73a
Children under 5 years old and pregnant women are most at risk1/2a
Most of the older treatments (e.g. chloroquine) are not effective anymore because of resistance3/14a
Artemisinin-based Combination Therapies (ACTs) have transformed the treatment of malaria in the past decade
Estimated incidence of malaria per 1,000 population in 20102/221-2
Source: WHO Malaria Report 2011
0-4 5-49 50-100 100-150 >150Data not available
2 | BASAID | Silvio Gabriel | April 2012 | Der Weg zur Eliminierung von Malaria | Business Use Only
The Novartis Malaria Initiative A holistic approach to best serve patients needs
Capacity building – patient-focused education and information Best practice sharing workshops for public health officials responsible for malaria control
State-of-the-art packaging and patient information developed specifically for not yet literate populations
Training material made available free of charge in several local languages
Access – affordability and availability are keyTreatment provided without profit to governments and NGOs
A 25-fold production increase since 200413
SMS for life: using mobile technology to help avoid stock-outs at health facility level14/3a
R&D – leading the path to malaria eliminationMass screening and targeted treatment of asymptomatic carriers10/ 1a; 11/1a
Next generation of malaria treatments12/1179a/22
Treatment – Coartem®,a story of firstsFirst fixed-dose ACT brought to market in 1999 and > 95% cure rate* with demonstrated safety profile4/940a,b; 5/547a,b; 6/251a,254b; 7/246a; 8/1824a
First ACT pre-qualified by the WHO for its efficacy, safetyand quality9/1a
First dispersible sweet- tasting ACT specifically developed for infants and children8/1820a
* 28-day PCR-corrected in evaluable population
3 | BASAID | Silvio Gabriel | April 2012 | Der Weg zur Eliminierung von Malaria | Business Use Only
500 million Coartem® treatments deliveredImpacting more than 1 million lives20
4.01.30.10.29
62
66
74
Treatmentsin millions
84
Funding uncertainGlobal policy uncertain
125%
580%
7%
12%
14%
Erraticorders
Supply challenges
ACT policy
adoption
ACT roll-out in public
sector
82
- 2%
Increase in production capacity (2001–2011)
Deliveries
100 100 100 100 100
Success in patient impact results in mortality reduction
Available production capacity
Novartis Malaria Initiative | April 20124
10022%
Together with our partners, and with our continued patient-centric approach…
5 | BASAID | Silvio Gabriel | April 2012 | Der Weg zur Eliminierung von Malaria | Business Use Only
6 | BASAID | Silvio Gabriel | April 2012 | Der Weg zur Eliminierung von Malaria | Business Use Only
The Novartis Malaria Initiative Four pillars of activities
7 | BASAID | Silvio Gabriel | April 2012 | Der Weg zur Eliminierung von Malaria | Business Use Only
No one should die of malaria.